Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.65 |
| ▸ | ALOX12 | P18054 | 4/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10203656 | 0.85 | KMT2A (0.61) | ALDH1A1ALOX12KMT2AKDM4EGAA | |
| SCHEMBL2605820 | 0.85 | KMT2A (0.56) | ALDH1A1ALOX12KMT2AKDM4EGAA | |
| SCHEMBL17993523 | 0.80 | ALDH1A1 (0.54) | ALDH1A1ALOX12KMT2AKDM4EGAA | |
| SCHEMBL10744953 | 0.77 | ALDH1A1 (0.56) | ALDH1A1ALOX12KMT2AKDM4EGAA | |
| SCHEMBL13608100 | 0.76 | MEN1 (0.58) | ALDH1A1ALOX12KMT2AGAALMNA | |
| SCHEMBL21101917 | 0.76 | KDM4E (0.55) | ALDH1A1ALOX12KMT2AKDM4EGAA | |
| SCHEMBL171970 | 0.75 | KMT2A (0.59) | ALDH1A1ALOX12KMT2ALMNACYP1A2 | |
| SCHEMBL5742233 | 0.75 | KDM4E (0.60) | ALDH1A1ALOX12KMT2AKDM4EGAA | |
| SCHEMBL4320604 | 0.75 | KDM4E (0.60) | ALDH1A1ALOX12KMT2AKDM4EGAA | |
| SCHEMBL14817477 | 0.74 | KDM4E (0.52) | ALDH1A1ALOX12KMT2AKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389541-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2013-03-05 | — | — | US | disclosed |
| US-20120108628-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | Mirati Therapeutics, Inc. | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108628-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | HGF, ERBB2, MET | ALDH1A1 3139/4885ALOX12 4236/4885KMT2A 2353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.